Directorate Change

RNS Number : 5439U

Oxford Biomedica PLC

16 October 2014

 



Directorate change: Additional Directorship

Oxford, UK - 16 October 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy company, announces that in accordance with Listing Rule 9.6.14R, it has been notified that Martin Diggle, a non-executive director, has been appointed as non-executive director of Proteome Sciences plc, with immediate effect.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Jessica Hodgson/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Group's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

RDNGGGUAUUPCGAQ